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A critical step in Plasmodium falciparum (Pf) host cell invasion is the formation of a tight 
junction between the parasite and the host cell, which provides a firm anchor to facilitate 
parasite entry. This step requires interaction between the micronemal protein AMA1 and 
RON2, a component of the parasite secreted RON receptor complex. This interaction is 
also required for efficient Pf sporozoite invasion of hepatocytes. This is a unique example 
in host-pathogen interactions where both ligand and receptor are provided by the parasite 
for successful host cell entry.  
We recently showed that a 49 amino acid region of RON2 (termed RON2L) is sufficient 
to bind AMA1 and block invasion, thereby acting as a potent entry inhibitor. RON2L and 
its binding pocket in AMA1 is conserved within each Plasmodium species and points to an 
evolutionarily preserved “lock-and-key” mechanism designed to prevent changes. We rea-
soned that targeting this interaction can be an effective antimalarial strategy as it would 
make it harder for the parasites to develop resistance. To do this, we are developing a novel 
gene therapy approach using adeno-associated virus (AAV) to endogenously express the 
entry inhibitor RON2L masked as a human Ig fusion protein (RON2L-Ig). We show that 
the entry inhibitor expressed by AAV transduction is produced as a correctly folded, stable 
fusion protein and potently neutralized P. falciparum merozoites in vitro. We are using a 
in vivo rodent malaria model and a P. falciparum humanized mouse model to evaluate 
protection against infection and disease. Our data indicate that self-targeting this critical 
invasion pathway used by both the transmitting and disease-causing forms of Plasmodium 
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Malaria is a life-threatening disease caused by Plasmodium parasites, and it is transmitted 
to people through bites of infected female Anopheles mosquitoes. In May 2017, World 
Health Assembly published the Global Technical Strategy for Malaria 2016–2030 (GTS)1 
that provides a comprehensive framework to guide countries in their efforts to accelerate 
the progress towards malaria elimination. Despite of large amount of investment made 
every year, malaria continues to pose one of the greatest threats to public health. There 
were 219 million clinical cases and an estimated 435,000 malaria deaths in 2017, mainly 
in Sub-Saharan Africa2. Data also suggested that no significant progress in reducing global 
malaria cases was made during the past few years, although the number of deaths has been 
reduced by almost 30% comparing to 2010. GTS sets the goal of reducing global malaria 
incidence and mortality rates by at least 90% by 2030. However, to reach its 2030 target, 
it is estimated that annual malaria funding will need to increase to at least US dollar 6.6 
billion per year by 2020.  
Current strategies to prevent and treat malaria include the use of insecticide-treated mos-
quito nets (ITNs), global access to rapid diagnostic tests (RDTs), and employing artemis-
inin-based combination therapy (ACT) to treat patients. While malaria control strategies 
have shown promising outcomes, significant challenges remain to be overcome if we are 
to achieve the quickly approaching 2020 and 2025 GTS milestones. Global reports of 2010-
2016 showed resistance to the four commonly used insecticide classes has been widely 
spread in all major malaria regions in the world3,4. Even more worryingly, multidrug-re-
sistant strains, including artemisinin-resistant P. falciparum, started to emerge in recent 
years independently in different countries, and spread between countries in the Greater 
2 
 
Mekong Subregion (GMS)5,6. Hence, the lack of a vaccine and the emergence of resistance 
to front-line antimalarials warrant development of novel approaches to prevent malaria. 
Plasmodium life cycle 
Malaria parasite Plasmodium is an obligate, unicellular eukaryotic parasite and belongs to 
a large phylum of parasitic alveolates called Apicomplexa. Most Apicomplexans, including 
Toxoplasma gondii, Plasmodium falciparum and other Plasmodium spp. possess a unique 
form of organelle that comprises a type of plastid termed apicoplast, which hosts important 
metabolic pathways like fatty acid synthesis, isoprenoid precursor synthesis, and parts of 
the heme biosynthesis pathway7. Life cycle of Plasmodium parasites involves multiple dis-
tinct stages in the vertebrate and mosquito vector (Figure 1)8. When an infected mosquito 
takes a blood meal from a vertebrate host (e.g. human), Plasmodium sporozoites, the inva-
sive forms that are present in the salivary gland of the insect, are injected into the dermis 
and stay there for at least thirty minutes9. Subsequently, the sporozoites enter the blood 
circulation and reach the liver, where they infect hepatocytes and undergo a large round of 
replication. At the end of intra-hepatic development thousands of merozoites are produced 
from each infected cell10. The released merozoites immediately infect erythrocytes and in-
itiate the blood-stage infection cycle. Generally, it takes parasites 24-72 hours (depending 
on the species) to undergo the asexual replication in red blood cells (RBCs). Inside RBCs, 
the parasites transform from rings to trophozoites, and finally mature to schizonts contain-
ing 16-32 merozoites, which are soon released following erythrocyte lysis. While the par-
asites go through continuous cycles of erythrocyte infection in the host blood stream, some 
will differentiate into sexual erythrocytic stage parasites, known as gametocytes. When 
both male (microgametocytes) and female (macrogametocytes) are ingested by a mosquito 
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during a blood meal, together they will go through the sporogonic cycle in the mosquito 
gut, resulting in the development of innumerable sporozoites that will finally migrate into 
the salivary gland of the mosquito and await for the next injection into vertebrate host and 
thus continuing the cycle11.  
Figure 1. Plasmodium parasite life cycle. 
Parasite invasion and the interaction between AMA1 and RON2 
Comprehensive understanding of parasite invasion mechanism can lead to discovery of 
drugs that effectively block the entry process of the parasite thus prevent malaria clinical 
symptoms, and more importantly, the massive number of replications in the host that cause 
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disease transmission. Electron microscopy studies have identified unique secretory orga-
nelles, such as the dense granules, micronemes, and rhoptries, located at the Plasmodium 
merozoite apical end and storing essential molecules for parasite egress and invasion (Fig-
ure 2). These molecules mainly belong to two families–erythrocyte binding-like (EBL) 
and reticulocyte binding-like homologues (Rh), respectively localizing to the micronemes 
and rhoptry neck12–16. Key event of the invasion process is the release of these molecules 
from the secretory organelles so that they can interact with host cell receptors and initiate 
entry process. Once merozoites are released from the infected RBCs, they are exposed to 
a low-potassium level environment, which triggers the calcium efflux from the endoplas-
mic reticulum (ER) and the translocation of microneme contents to the merozoite surface17. 
Invasion of Plasmodium spp. merozoites begins with an initial weak attachment, followed 
by an active process of reorientation that ultimately brings the apical end of the parasites 
into close apposition with the RBC surface18,19. Consequently, this event triggers the for-
mation of a moving junction, which can be observed by transmission electron microscope 
(TEM) manifesting as a dense region under the cytoplasm of RBC; meanwhile the mero-
zoite secretes its rhoptry contents that facilitate the invasion process20—having the moving 
junction as a firm anchor for entry, the parasite actin-myosin motor drives the cell motility 
and pull the merozoite into the RBC21.  
Among all the identified invasins to date, apical membrane antigen 1 (AMA1) is consid-
ered as one of the most promising targets for vaccine and therapeutics development due to 
its critical role in parasite’s invasion process22–24. AMA1 is a protein initially localized 
inside micronemes of the parasite in the form of an 83 kDa precursor25,26, and later trans-
located onto the surface in a 66 kDa form by the time of schizont rupture and release of 
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merozoites27,28. AMA1 is unique to Apicomplexan parasites and derives from a single es-
sential gene present in all Plasmodium species29. Immunoprecipitation experiment of 
AMA1 in the parasite detergent extracts identified a complex of rhoptry neck proteins 
(RONs)30,31. Interestingly, RON complex appears to be secreted by the parasite into and 
translocate across the RBC membrane, where it serves as the receptor for AMA132. RON2 
is found to be the only transmembrane protein in the RON complex that interact directly 
with AMA1 by inserting its second and third hydrophobic helices into the hydrophobic 
pocket of AMA1 (Figure 3)32–38. Recently, the interaction between AMA1 and RON2 has 
been found to be critical for triggering junction formation, and it depends on the presence 
of two conserved Cys residues within the RON2 sequence between the second and the third 
hydrophobic helices, termed RON2L32. It was also shown that unlike other steps where 
functionally redundancy exists, the junction formation induced by the interaction between 
AMA1 and RON2 in Plasmodium spp. has no alternative pathways32. The same study also 
showed that the number of invasion event was significantly reduced by having the short 
peptide RON2L in the parasite culture. Importantly, RON2L and its binding site on AMA1 
are both conserved among all Pf genetic variants33,34. In addition, studies have confirmed 
that such invasion mechanism is also shared in pre-erythrocytic stage parasite invasion 
process, and a RON2L-like molecule was shown to have an inhibitory effect on sporozoite 
invasion into hepatocytes39,40. These evidences point at a functional constraint governing 
an essential step in parasite invasion and represent a novel target can potentially be ex-






Figure 2. Crucial organelles and molecules for merozoite invasion. Important molecules for 
parasite invasion and their corresponding locations are listed on the right. 
AMA1-RON2 as anti-malarial target 
Evidence of AMA1 polymorphism has been reported since 199041. One of the most striking 
evidence is that a single trial site in Mali identified strikingly 214 AMA1 variants in total 
among 506 subjects, indicating an extreme sequence diversity of AMA142. Immune re-
sponses have been thought to be the predominant selective factor for the mutations, hence 
also has encouraged a belief that immune responses to AMA1 can indeed have a parasite-
inhibitory effect in humans43. AMA1 has been a leading blood-stage malaria vaccine can-
didate, however, its polymorphism continues to be the greatest obstacle towards the devel-
opment of a successful vaccine. To date, two phase 2 trials have been conducted to measure 
the protective effect of AMA1 vaccines, but both showed either no significant efficacy or 
only average protection against vaccine-type parasites44,45.  
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Discouraged by the vaccine trial results, alternative methods that target AMA1-RON2 in-
teraction has been sought. Recent vaccination studies using a pre-formed AMA1-RON2L 
complex instead of individual antigens in a mouse malaria model showed great protection 
against a highly virulent Plasmodium yoelii YM parasite. Antibodies induced after vac-
cination of the complex showed an increased inhibitory activity largely due to distinct tar-
get sites on new AMA1 epitopes surrounding the RON2-binding pocket46. A follow-up 
study showed the complex vaccine in Freund’s adjuvant also provided protection in Aotus 
monkeys against a virulent P. falciparum infection47. In addition, small molecules that can 
block AMA1-RON2 interaction were identified by screening a library of over 21,000 com-
pounds48, providing an additional path towards malaria treatment.  
Neutralizing antibodies and their coordinating Fc-receptors play key roles in malaria ther-
apeutics49. Natural antibodies elicited by AMA1 vaccines often target the highly polymor-
phic region of the protein thus the parasite can easily evade antibody neutralization through 
mutation and evolution50,51. Here we aim to design an antibody-like inhibitor which can 
competitively bind to the conserved region of the invasion ligand AMA1 thus block para-
site invasion. To do this, we utilize the binding peptide RON2L which, as described above, 
insert itself into the conserved hydrophobic pocket of AMA1. We replaced the variable 
regions on both the light and heavy chains of a human IgG1 antibody with RON2L peptide, 
resulting in a tetravalent inhibitor which, henceforward termed “RON2L-Ig”, can poten-
tially bind to four AMA1 molecules at the same time. It is called “self-targeting” due to 
the fact that RON2L is a parasite-originated peptide that binds to the parasite ligand AMA1. 
We reason that the human immunoglobulin (Ig) which has a relatively large size (~150 
kDa) can mask the foreign peptide RON2L, thus preventing the inhibitor from inducing an 
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immune response. We also reasoned that in addition to the direct blocking effect, once 
tagged by the inhibitor, parasites can be efficiently engulfed and processed by antigen pre-
senting cells (APCs) with receptors that recognize the Fc region of the inhibitor, and po-
tentially further leads to a therapeutic vaccination effect. Additionally, previous studies 
have shown that the Fc region on the human IgG facilitates clearance of parasites through 
antibody-dependent cellular cytotoxicity (ADCC)52,53, a mechanism of cell-mediated im-
mune defense whereby an effector cell of the immune system (e.g. monocytes) actively 
lyses a target parasite by recognizing the Fc region of the antibodies binding to the mem-
brane-surface antigens. Finally, Fc region of the inhibitor may also recruit C1q from com-
plement system and activate complement fixation, ultimately leading to parasite lysis54.  
 
Figure 3. Illustration of AMA1-RON2 interaction. (A) Apical end of the parasite in close contact 
with RBC surface, and a dense region under the RBC cytoplasm can be observed. (B) AMA1 
interaction with RON complex at the interface between parasite and host cell. (C) Note that only 
the ectodomain of the RON2 protein interact directly with AMA1 by inserting itself into the 
hydrophobic pocket of AMA1. 
Adeno-associated viral vector for malaria prophylaxis  
The most common viral vector that has been employed in gene therapy studies and clinical 
trials is adeno-associated virus (AAV), a nonenveloped virus from Parvoviridae family 
that infects humans and other primate species. AAV is replication-defective in the absence 
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of helper viruses, such as adenovirus and herpes simplex virus55,56. Currently no known 
disease is reported to be caused by AAV apart from a very mild immune response57. So far 
it has been discovered that AAV has as many as 11 serotypes with distinct tropism towards 
various cell types—serotypes 2, 3, 5, and 6 infects human cells, while the rest are found to 
infect nonhuman primates58. In contrast to the wild-type virus, recombinant AAV enters 
human and nonhuman primate cells and persists in an extrachromosomal state without in-
tegration into host cell genome, although a low frequency of random integration that leads 
to genetic toxicity has been reported57,59,60. Multiple AAV-based gene therapies are being 
tested in clinical trials, including Hemophilia61, congestive heart failure62, Parkinson’s dis-
ease63. The first AAV-based gene therapy licensed in the world is Alipogene tiparvovec 
(Glybera) that is used to treat lipoprotein lipase deficiency (LPLD)64,65; while in the U.S., 
it is not until the beginning of last year that the first AAV-based gene therapy called LUX-
TURNA™ by Spark Therapeutics was approved for treating inherited blindness disorder 
biallelic RPE65 mutation-associated retinal dystrophy66.  
An alternative option to immunization is viral vector-mediated passive delivery of effector 
genes (e.g. pathogen-specific antibodies). Such technique is called vectored immune-
prophylaxis (VIP), and was first pioneered by Johnson et al. in 2009, where it was showed 
that AAV-delivered immunoadhesins could protect most rhesus macaques from a simian 
immunodeficiency virus SIVmac316 challenge67. Subsequent studies using AAV-medi-
ated in vivo expression of monoclonal antibodies reported high level antibody production 
which is maintained for several months after a single intramuscular injection, and protected 
humanized mice and macaques against HIV, influenza A virus, and transgenic Plasmodium 
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parasite68–71. On the other hand, AAV has also been employed to deliver artificially de-
signed inhibitor drugs for blocking pathogen entry. For example, inhibitor drug eCD4-Ig 
comprising of domains 1 and 2 of the CD4 receptor and a small CCR5-mimetic sulfopep-
tide together fused to a human IgG1 Fc domain was shown 100% neutralization efficiency 
of a diverse panel of neutralization-resistant HIV-1, HIV-2, and SIV isolates, including a 
comprehensive set of isolates resistant to the CD4-binding site bNAbs VRC01, NIH45-46 
and 3BNC117; when delivered by an AAV vector, the drug eCD4-Ig provided a great pro-
tection from SHIV infection in non-human primate model72. Moreover, a strong ADCC 
effect was observed by following studies, suggesting an additional protection effect con-
tributed by the Fc region of the inhibitor73,74.  
Here we propose to employ AAV vector to deliver the gene of our inhibitor RON2L-Ig for 
malaria prophylaxis. We aim to first engineer a recombinant AAV that is used for trans-
ducing animals and inducing in vivo expression of the Plasmodium entry inhibitor RON2L-
Ig. WE expect that this will result in durable, systemic expression of stable inhibitor from 
rAAV transduced muscle cells. Upon challenge with blood-stage malaria parasites, 
RON2L-Ig present in circulation is expected to bind to AMA1 on the surface of merozoites, 
preventing them from engaging with Plasmodium secreted RON2 receptor on host cells, 
thereby neutralizing parasites before their invasion into RBCs. In addition, upon sporozoite 
challenge through infected mosquito bite, RON2L-Ig is expected to also bind to AMA1 on 
the sporozoite surface and preventing the parasite from reaching and infecting the hepato-
cyte. The dual mode of action of this Plasmodium self-targeting entry inhibitor could there-
fore prevent both infection as well as confer protection against disease.  
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Material and Methods 
Construction and cloning of pcDNA™3.1-PfRON2L-Ig and pAAV-Py-
RON2L-Ig  
 
Figure 4. Plasmid maps of (A) pcDNA™3.1-PfRON2L-IgVL, (B) pcDNA™3.1-PfRON2L-IgVH, 






To express b12 (anti-HIV-1 gp120) and 2A10 (anti-P. falciparum CSP) antibodies in mice, 
their DNA sequences of the variable regions were synthesized based on published se-
quences and cloned into the VIP expression vector as previously described68,71. This was 
done in Dr. David Baltimore’s laboratory at California Institute of Technology by Dr. 
Alejandro Balazs and tested further by Dr. Cailin Deal in Dr. Gary Ketner’s laboratory at 
Johns Hopkins Bloomberg school of Public Health. These previously studied VIP expres-
sion vector plasmids were used in this study as controls. For engineering the VIP vector 
that expresses the gene of our inhibitor used in rodent model, 2A10 antibody variable re-
gions on both heavy and light chains were replaced with synthesized PyRON2L from pub-
lished sequence (Figure 5)32. The 2A10 heavy chain variable region was removed by di-
gesting the plasmid with NotI and SacI restriction enzymes at 37 °C overnight, then Gibson 
Assembly was performed by adding synthetic PyRON2L-Ig_VH insert at 3:1 ratio into the 
gel purified double digested pAAV at 50 °C for one hour. 2A10 light chains were replaced 
with synthetic PyRON2L-Ig_VL insert following the same process. After excising the var-
iable region of 2A10 heavy and light chains and substituting the RON2L sequence, 30 
seconds of heat-shock transformation at 42 °C using XL10-Gold® Ultracompetent Cells 
was performed. Following transformation, cells were plated on prewarmed LB agar plates 
with 100 µg/mL ampicillin for selection, and the plates were incubated at 37 °C overnight. 
On the next day, positive clones were identified by colony PCR. ZymoPURE™ II Plasmid 
Midiprep Kit was used to purify plasmid DNA from 1 L of bacteria culture, and the con-




To produce inhibitor for in vitro characterizations, 2A10 antibody variable regions on both 
heavy and light chains were replaced with synthesized PfRON2L from published se-
quence32, then the entire PfRON2L-IgG_VH-PfRON2L-IgG_VL region was cut off from 
the VIP vector and inserted into a pcDNA™3.1 vector. pcDNA™3.1 vector purchased 
from Thermo Fisher Scientific contains a cytomegalovirus (CMV) enhancer-promoter for 
high-level expression, a large multiple cloning site in either forward (+) or reverse (−) ori-
entations, a Bovine Growth Hormone (BGH) polyadenylation signal and transcription ter-
mination sequence for enhanced mRNA stability, a SV40 origin for episomal replication 
and simple vector rescue in cell lines expressing the large T antigen, and Ampicillin re-
sistance gene and pUC origin for selection and maintenance in E. coli. This vector was 
chosen due to its optimal performance in transfection of mammalian cell lines. Maps of the 
plasmids described above are shown in Figure 4. 
To increase the flexibility of the inhibitor, a Gly-Gly-Ser-Gly linker was added between 
the RON2L peptide and CH1 of the heavy chain or CL of the light chain. Gly and Ser were 
used because of their small sizes that allow flexible movement, while at the same time Ser 
helps maintain stability of the structure through formation of hydrogen bonds with water 
molecules thus avoid undesired interactions75,76. In addition, signal sequence (SS) was 
added to 5’ end of both heavy and light chain. Signal peptides are important for transporting 
newly synthesized proteins from ER to cell exterior across membrane, and experiments 
showed that mutations in the signal peptide sequence resulted in decrease in the secretion 
efficiency of the antibody77. These features are shown in the schematic representation of 
the VIP expression vector in Figure 5. 
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Figure 5. Schematic representation of VIP expression vector. 
Production, purification, and quantification of inhibitor 
To begin with, frozen Human Embryonic Kidney 293T cells (previously preserved in freez-
ing medium composed of 90% complete medium and 10% DMSO) were thawed and cul-
tured in a 5% CO2 incubator at 37 °C in complete medium (Dulbecco's Modified Eagle's 
Medium, 10% fetal bovine serum). After confluency reaches 70-80%, cells were trans-
fected with pcDNA-PfRON2L-Ig_VH and pcDNA-PfRON2L-Ig_VL at 1:1 ratio mixed 
with jetPRIME reagent and buffer according to manufacturer’s protocol78. For each T175 
flask, 10 μg of plasmid in total, 1.25 mL of jetPRIME buffer, and 50 μL of jetPRIME 
reagent were mixed and added to the culture medium. Cell culture supernatant was col-
lected every 48 hours and filtered (Millipore) after adding protease inhibitor, then stored at 
4 °C.  
Two different methods, ammonium sulfate precipitation and sodium sulfate precipitation, 
were tested first to compare their efficiency. Saturated ammonium sulfate solution was 
prepared by adding excess solid (NH4)2SO4 to distilled water (about 950 g to 1 L) and 
stirred overnight at room temperature. This solution (in contact with solid salt) was stored 








at 4 °C for use. Saturated ammonium sulfate solution was added drop-wise into the super-
natant collection to produce 50% final saturation and stirred at 4 °C overnight. On the next 
day, solution was centrifuged at 4,000 rpm for 1 hour at 4 °C. The supernatant was dis-
carded, and remaining liquid was drained by carefully inverting the tube over a paper tis-
sue. For sodium sulfate purification, solid Na2SO4 was added to produce an 18% w/v so-
lution (i.e., add 1.8 g/10 mL), and stirred at 25 °C for 30 minutes to 1 hour. Next, the 
solution was centrifuged at 4,000 rpm for 1 hour at 25 °C. The supernatant was discarded, 
and the pellet was drained on a paper tissue. Finally, after finishing either method, the pellet 
was dissolved in PBS in 10% volume comparing to that of the original supernatant and can 
be stored at 4 or −20 °C until affinity purification.  
To purify the modified IgG, equal volume of IgG binding/washing buffer (G-Biosciences) 
was added and mixed with PBS dissolved pellet. Protein G column was equilibrated with 
30 mL of IgG binding/washing buffer at room temperature, then the 1:1 diluted solution 
was added on to the column and let flow through by gravity. Next, the column was washed 
with 10 mL of IgG binding/washing buffer again, followed by elution using 5 mL of IgG 
elution buffer (G-Biosciences) into a 30 kDa filtration tube containing 150 µL of pH 9.0 
Tris-HCl for neutralization. The inhibitor protein went through multiple rounds of dialysis 
by centrifuging at 4 °C 4,000 rpm to replace the buffer with incomplete RPMI. Finally, the 
inhibitor protein in incomplete RPMI was sterile filtered through a 0.22 µm filter unit and 
kept at 4 °C. 
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Inhibitor characterization  
Purified RON2L-Ig was loaded on an SDS-PAGE protein gel at 100V for 1 hour. The 
protein gel was washed in water for four times to remove SDA, then stained with Coo-
massie blue for 2 hours. For western blot analysis, the SDS-PAGE gel was transferred to a 
methanol-activated PVDF membrane using an Invitrogen Power Blotter at 1.3 Amp for 10 
minutes. Next, the PVDF membrane was blocked with Thermo Fisher Scientific SuperB-
lock Blocking buffer and 0.1% TWEEN 20 on the shaker overnight. The next day, second-
ary antibody (Alkaline phosphatase conjugated anti-human IgG antibody) was diluted in 
blocking buffer 1:2,500 and incubated with membrane at 4 °C on the shaker for 2 hours. 
Subsequently, the membrane was repeatedly washed with wash buffer (1× PBS and 1% 
TWEEN 20) for 10 minutes. 1 mL of West Blue® Stabilized Alkaline Phosphatase sub-
strate for was added to the membrane, and the reaction was neutralized by washing with 
distilled water.  
For quantification of human IgG expression level, standard enzyme-linked immunosorbent 
assay (ELISA) was performed (Table 1). 0.02 μg of goat anti-human IgG-Fc antibody 
(Bethyl) was added into each well of the plate and incubated overnight at 4 °C. The next 
day, plate was blocked with 200 µL blocking buffer (1% BSA Sigma in 1× PBS and 0.1% 
TWEEN 20) per well for 1 hour. Meanwhile samples were four-fold serially diluted in 
blocking buffer on a clean 96-well plate. 100 µL of each sample dilution was transferred 
to the ELISA plate and incubated for 1 hour at room temperature. Plate was then washed 
for four times with wash buffer (1× PBS and 0.1% TWEEN 20) and incubated with 100 
µL per well of HRP-conjugated goat anti-human kappa light chain antibody (Bethyl) 
1:10,000 diluted with blocking buffer for 1 hour at room temperature. Plate was washed 
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again four times, then 100 µL of TMB Super Sensitive 1-Component HRP Microwell Sub-
strate was added into each well. The plate was incubated in the dark for 2 minutes at room 
temperature, followed by neutralization with 100 µL Stop Solution for TMB Substrates. 
Plate was read at a wavelength of 450 nm using a microplate reader. A standard curve was 
generated based on the reading of Human Reference Serum (Bethyl), and OD data of the 
samples were interpolated using the standard curve to calculate hIgG concentration.  
For characterizing inhibitor’s binding activity against AMA1 molecule, ELISA plates were 
coated with 0.1 µg of P. falciparum recombinant AMA1 molecule per well overnight at 4 
°C. Other steps were performed as described above. PfRON2L-Ig_VH and VL, 1:2,500 di-
luted anti-human Alkaline Phosphatase conjugated anti-hIgG (H+L) secondary antibody 
was used for detection, followed by adding Sigma-Aldrich Phosphatase substrate and read 
at 405 nm wavelength using a microplate reader. ELISA coating and primary reagent spec-
ifications are summarized in Table 1. 







region antibody  
Cell culture supernatant: 
1/1; Mouse sera: 1/5,000; 
HRS: 2 ug/mL; Precipi-
tated protein: 1/50; Protein 





PfAMA1 molecule  
Precipitated protein: 1/5; 




Mouse sera PyRON2L molecule Mouse sera: 1/5,000; 
Mouse anti-hIgG Mouse sera hIgG Mouse sera: 1/5,000; 
Table 1. Coating and primary reagent specifications for ELISA. 
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Immunofluorescent assay (IFA) was performed to confirm that RON2L-Ig inhibitor could 
bind to its natural AMA1 ligand in the parasite. P. falciparum infected blood smears were 
made from parasite culture containing mature schizonts. Fixative solution (2.5% PFA, 
0.1% GA, 3% sucrose) was added to the slides and incubated for 10 minutes, then aspirated 
with vacuum, following by washing with 1× PBS for 3 times. Next, blocking buffer (1× 
PBS, 2% BSA, 0.1% Triton X-100) was added on the slides and incubated for 1 hour at 
room temperature. Purified inhibitor PfRON2L-Ig diluted 1:100 in blocking buffer was 
added to the slides, then gently covered with a coverslip (to avoid the coverslip contacting 
the smears). The slides were incubated at 4 °C overnight. On the next day, the slides were 
washed with wash buffer (1× PBS and 0.1% Triton) for 5 times. Secondary antibody (488 
goat anti-human antibody) 1:200 diluted was added to the slides and kept in dark for 2 
hours, then washed with wash buffer. Finally, 5 μL of ProLong™ Gold Antifade Mountant 
mounting solution was added to the smears and mounted with coverslips. Anti-AMA1 an-
tibody (1:1000 dilution) was added to confirm co-localization with PfRON2L-Ig. Anti-
rabbit Alexa Fluor® 633 was used on secondary antibody.  
Finally, growth inhibitory assay was performed to demonstrate that the inhibitor was capa-
ble of neutralizing parasite in vitro and preventing its invasion into RBCs. 1 L of complete 
media (CM) was prepared by adding 5 g of Albumax, 30 mL of NaHCO3, and 2.6 mL of 
gentamycin into 967.4 mL of Roswell Park Memorial Institute (RPMI) 1640 Medium. To 
do this, parasites were first synchronized at late schizont stage by Percoll/sorbitol synchro-
nization method as previously described79. Briefly, 90% Percoll with 6% sorbitol was pre-
pared by adding 12 g of D-Sorbitol into the mixture of 20 ml of 10× RPMI-HEPES and 
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180 ml of Percoll. 70% Percoll-sorbitol was prepared by mixing 37.5 mL of 90% Per-
coll/6% soribitol solution with 10.5 mL of 1× RPMI-HEPES. 40% Percoll-sorbitol was 
prepared by mixing 21 mL of 90% Percoll/6% sorbitorl solution with 27 mL of 1× RPMI-
HEPES. Gradients were prepared into a 17×100 mm tube, starting with 70% Percoll/sor-
bitol and overlaying with the others in sequence of 3 mL of 70% Percoll/sorbitol, 3 mL of 
40% Percoll/sorbitol, then 1-2 mL of parasite solution. Gradients were centrifuged at 
10,000 rpm for 20 min at RT, then parasitized RBCs at the interface between 40% and 70% 
Percoll/sorbitol were collected and transferred to a new 50 mL tube. Incomplete media was 
added dropwise to the parasitized RBCs, then centrifuged again at 400 g. Lastly, cells were 
washed with the same volume of incomplete media (iCM) and finally cells were resus-
pended in 1 mL of CM.  
Parasitemia of the synchronized parasite culture was calculated by counting the proportion 
of parasite-infected RBCs on a prepared blood smear slide under light microscope. Ac-
cordingly, parasite culture was diluted to 0.5% parasitemia by adding additional 2% hem-
atocrit CM. The parasite culture was collected in a 15 mL tube and centrifuged at 2,500 
RPM for 5 min, then the media was removed and replaced with equal volume of 2× CM. 
Inhibitor protein was serial diluted with iCM on a half-area 96-well plate, then equal vol-
ume of parasite culture in 2% hematocrit 2× CM was added to each well. Consequently, 
each well contained 0.5% parasitemia 1% hematocrit 1× CM. E64D (50 μM) and EGTA 
(4 mM) were used as positive control. At the end of 48 hours, 5 μL of the completely 
resuspended parasite culture was taken from each well of the plate and mixed with 40 μL 
staining solution (1× PBS, 1:10,000 dilution of SYBR Green, and 1:10,000 dilution of Mi-
toTracker) by constantly shaking in dark for 30 min. Subsequently, 200 μL of 1× PBS was 
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added to each well and mixed by shaking. At least 10,000 cells from each sample were run 
in the Invitrogen™ Attune™ NxT Flow Cytometer to detect cell fluorescence.  
Production and purification of AAV-PyRON2L-Ig recombinant virus 
Triple-plasmid transfection is the most common approach to generate recombinant AAV 
(Figure 6, adopted from SignaGen website)80,81. The AAV genome is a molecule of sin-
gle-stranded DNA of approximately 4.7 kb, with inverted terminal repeats (ITRs) that form 
T-shaped, base-paired hairpin structures at either end. Between ITRs at both ends are two 
genes (rep and cap) encode for four nonstructural proteins required for replication (Rep78, 
Rep68, Rep52, and Rep40) and three structural proteins that make up the capsid (VP1, 
VP2, and VP3). For the purpose of efficiently producing recombinant AAV, the rep and 
cap genes are deleted from the viral genome and provided in trans on a separate plasmid. 
The gene of interest is cloned into an expression plasmid flanked by the AAV ITRs. Ge-
nomic elements originated from adenovirus, including E1A, E1B, E2A, E4, and VA RNA 
region, are identified to be essential for AAV replication. Since HEK293T cell stably ex-
presses the E1A and E1B proteins, only E2A, E4, and VA RNA region are included in the 
helper plasmid82. 
Figure 6. Triple-plasmid transfection for recombinant AAV production. 
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The method followed to prepare AAV vector virus expressing the 2A10 mAb has been 
previously described71. Briefly, three days before transfection, four 15 cm plates were 
seeded with 3.75 × 106 HEK293T cells each in 25 mL of DMEM and these plates were 
maintained in a 5% CO2 incubator at 37 °C. Approximately 2 hours before transfection, 
the media in the plates were removed and replaced with 15mL of fresh DMEM containing 
10% FBS, 1% P/S and 1% L-Glu (referred to as complete DMEM or cDMEM). 197 μg of 
AAV8 rep & cap DNA, 98.4 μg of helper vectors pHELP DNA (Applied Viromics) and 
24.6 μg of pAAV-PyRON2L-Ig plasmid DNA were mixed together in a 50 mL tube. Then 
16 mL of complete DMEM, 240 µL BioT was added and vortexed. The DNA was mixed 
with BioT and cDMEM mixture, vortexed and incubated for 5 min at room temperature, 
then 4 mL of this mixture was added to each 15 cm plate. The supernatant was collected 
and replaced with 15 mL fresh cDMEM media at five time points after transfection (36, 
48, 72, 96, and 120 hours post-transfection). The supernatant was passed through a 0.22 
µm filter (Millipore) and stored at 4 °C. At the end of the fifth collection, 75 mL of 5× PEG 
solution (40% polyethylene glycol, 2.5 M NaCl) was added to approximately 300 mL of 
supernatant. The virus in the supernatant was allowed to precipitate on ice for 24 hours at 
4 °C. After precipitation, the solution was centrifuged (Sorvall RC5C centrifuge) at 5,000 
RPM for 30 min at 4 °C, then the supernatant was discarded. The pellets were resuspended 
in 1.37 g/mL CsCl solution and then transferred to two Sorvall quick seal tubes. To form a 
gradient, the solution was centrifuged (Sorvall WX ultracentrifuge) at 60,000 RPM for 24 
hours at 20 °C. Fractions (100-150 µl per well) were collected in a 96 well flat bottom 
plate, and refractive index of each of these fractions were determined using a refractometer. 
Fractions with a refractive index between 1.3755 and 1.3655 (which contained rAAVs) 
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were combined and the final volume was made up to 15 mL by adding Test Formulation 
Buffer 2 (TFB2, 100 mM sodium citrate, 10 mM Tris pH 8). The solution was pipetted on 
to a 100 kDa MWCO centrifugal filter (Millipore) and centrifuged at 4,000 RPM (Sorvall 
legend RT series centrifuge) at 4 °C for 30-45 min or till the retentate was below the 1 mL 
mark. This step was repeated for five times to wash the virus, each time adding 15 mL of 
TFB2 to the filter and repeating centrifugation. The membranes were washed with 300 µL 
of TFB2 and the final retentate was aliquoted and stored at −80 °C. 
rAAV quantification 
The unknown AAV virus and standard sample (AAV8 virus expressing b12 mAb-1×1012 
GC/mL) were diluted tenfold in DNase buffer and 10 units of DNas I (Roche) was added to 
each sample. The samples were incubated at 37 °C for 30 mins. The Unknown AAV sam-
ples were diluted in DPEC treated water to 1:1,000, 1:10,000 and 1:100,000. The standard 
curve was created by diluting the standard sample four-fold in DPEC treated water from 
2×1010 GC/mL to 0 GC/mL. A PCR mix containing 8.2 µL of SYBR green, 2 µL of DPEC 
treated water and 0.33 µL of forward and reverse primers (5’ CMV: AACGCCAA-
TAGGGACTTTCC and 3’ CMV: GGGCGTACTTGGCATATGAT) or the luciferase 
transgene (5’ Luc: ACGTGCAAAAGAAGCTACCG and 3’ Luc: AATGGGAAGTCAC-
GAAGGTG) per sample was prepared. 10 µL of PCR mix and 5 µL of sample were added 
to the 96-well PCR plate. The samples were run in duplicates in the MicroAmp Fast Optical 
96-Well Reaction Plate. The copy number of rAAV in the samples were quantified using a 
quantitative PCR machine (Applied Biosystems™ One Step Plus qPCR) with the following 
program: one cycle of 50 °C for 2 minutes, one cycle of 95 °C for 10 minutes, 40 cycles of 
95 °C for 15 seconds and 60 °C for 60 seconds.  
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rAAV transduction  
Aliquots of previously titered viruses were thawed on ice and diluted in TFB2 to achieve 
the predetermined dose of 1.5x1011 GC in a 100 µL volume. Inbred 3- to 4-week old 
C57BL/6 (Jackson Laboratories) female mice, in groups of five, each was given a single 
100 µL intramuscular (i.m.) injection into the cranial thigh muscle with a 29G needle. After 
vector administration, blood was collected from the tail weekly starting from week 3. Tubes 
were stored at 4 °C for 1 hour, then was spun for 10 minutes at 5,000 RPM to separate sera. 
Sera was collected and stored at −20 °C. 
Inhibitor in vivo properties characterization  
Mouse sera was diluted 1:5,000 with sterile blocking buffer (1% BSA in PBS and 0.1% 
TWEEN 20) as starting dilution for ELISA. For quantification of human IgG expression 
level: 100 µL diluted goat anti-human IgG-Fc antibody (Bethyl) was added in each well of 
the plate and incubate overnight at 4 °C. On the next day, 200 µL of blocking buffer was 
added to each well and incubated for 1 hour. Serum samples were serially diluted in block-
ing buffer starting from 1:5,000 on a clean 96-well plate. 100 µL of each sample dilution 
was added to the ELISA plate and incubated for 1 hour at room temperature. Plate was 
washed with wash buffer (1×PBS and 0.1% TWEEN 20) and incubated with 100 µL per 
well blocking-buffer-diluted HRP-conjugated goat anti-human kappa light chain antibody 
(1:10,000; Bethyl) for 1 hour at room temperature. Plate was washed again for four times, 
then 100 µL of TMB Super Sensitive 1-Component HRP Microwell Substrate was added 
into each well. The plate was incubated in the dark for 2 minutes at room temperature, 
followed by neutralization with 100 µL Stop Solution for TMB Substrates. Plate was read 
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at a wavelength of 650 nm then deduced by 450 nm signal using a microplate reader. A 
standard curve was generated based on the reading of Human Reference Serum (Bethyl), 
and OD data of the samples were interpolated using the standard curve to calculate the 
human IgG concentration in mice serum. 
Immunofluorescent assay: blood smears were made from donor mice that were injected 
with P. yoelii parasites. Fixative solution (2.5% PFA, 0.1% GA, 3% sucrose) was added to 
the slide and incubated for 10 minutes, then aspirated with vacuum and the slide was 
washed with 1× PBS for 3 times. Next, blocking buffer (1× PBS, 2% BSA, 0.1% Triton X-
100) was added on the slide and incubated for 1 hour at room temperature. Serum diluted 
1:100 in blocking buffer was added to the slide, then gently covered with a coverslip (to 
avoid the coverslip contacting the smears). The slides were incubated at 4 °C overnight, 
then were washed with wash buffer (1× PBS and 0.1% Triton) for 5 times the next day. 
Secondary antibody (488 goat anti-human antibody) 1:200 diluted was added to the slide 
and kept in dark for 2 hours, then washed with wash buffer. Finally, 5 μL of ProLong™ 
Gold Antifade Mountant mounting solution was added and mounted with coverslips. An-
tibody to PyAMA1 (1:1,000 dilution) was added to confirm co-localization with Py-









Figure 7. In vivo experiments overview. (I) Tissue culture is transfected with three plasmids: 
pAAV with gene of interest, pHelp, and rep and cap plasmid. (II) rAAV particles were precipitated 
and purified from the culture supernatant, followed by (III) RT-PCR quantification. (IV) Total 
1.5×1011 GC of rAAV per mice is injected in the leg muscle, and in vivo expression level of the 
inhibitor is followed by weekly bleeding of the animal and human IgG quantification in the mouse 
sera by ELISA. (V) Once the inhibitor level starts to plateau starting from week 8, the mice are 
challenged with P. yoelii blood-stage parasites. (VI) Lastly, protection effect of the inhibitor is 
monitored by a daily bleeding of the animal and comparing the parasitemia of the blood smears 






Optimization of transfection  
BioT is a lipid-based reagent designed and formulated with proprietary technology for 
transfecting DNA, siRNA and anti-sense oligonucleotides into a variety of eukaryotic cell 
lines, insect cells, and cells of primary culture and suspension culture83. BioT is what orig-
inally used in the Baltimore lab protocol for triple-plasmid transfection to produce recom-
binant viruses, yielding high copy number of recombinant viruses. However, for the pur-
pose of producing proteins, previous experience with BioT resulted in low expression level. 
Hence, optimization of this process is required to obtain a higher transfection efficiency.  
jetPRIME® is a novel powerful transfection reagent based on a polymer formulation man-
ufactured at Polyplus-transfection®, and it only requires low amounts of nucleic acid per 
transfection, hence resulting in very low cytotoxicity. We compared transfection efficiency 
of green fluorescent protein (GFP) after transfecting HEK293T cells using the same 
amount (2 μg) of plasmid containing GFP with either BioT or jetPRIME. GFP expression 
was monitored using a fluorescent microscope (Figure 8A & 8B). Transfection with 
jetPRIME resulted in superior transfection efficiency as observed by the higher number of 
cells expressing GFP on the plate using jetPRIME with similar cell confluency as the plate 
using BioT (Figure 8C & 8D). Henceforth jetPRIME system was used for subsequent 





Figure 8. Transfection reagent optimization. GFP expression level in cells transfected with BioT 
(A) or jetPRIME (B) on 293T cell plates with similar cell confluency observed under bright field 
(C & D). 
Inhibitor binds to its natural parasite ligand AMA1  
ELISA data showed that in the cell culture supernatant, both heavy and light chain of the 
RON2L fusion protein were produced at high level. Importantly, these fusion proteins were 
able to bind to AMA1 individually (Figure 9A). Next, we examined the optimal HC:LC 
ratio for transfection to produce maximum RON2L-Ig quantity. Four different ratios were 
tested, while no significant difference in total Ig between them was observed, 1:1 ratio 
appears to have higher yield and stronger AMA1 binding activity (Figure 9B). Next, we 
tested the duration of recombinant RON2L-Ig protein expressed in the transfected 293T 
cells. To do this, we collected culture supernatant at different day following transfection 
and measured total Ig and its AMA1 binding activity. Inhibitor was produced at consist-
ently high levels in 293T cell culture over the 2 weeks tested (Figure 9C).  





In addition to inhibitor’s ability to bind 3D7 AMA1, we also showed its specificity to bind 
AMA1 variants of different strains of P. falciparum parasites. The inhibitor showed similar 
binding affinity to both Pf 3D7 and PfFVO AMA1, indicating that the recombinant 
RON2L-Ig indeed has cross-strain specificity (Figure 9D).  
 
Figure 9. Characterization of PfRON2L-Ig by ELISA. (A) HC and LC expression in 293T cells 
(anti-hIgG) and their binding activity to AMA1 (schematic representation of HC and LC is shown 
on the top of each column), (B) testing different plasmid ratios of HC:LC plasmids for transfection 
for optimal inhibitor expression (anti-hIgG) and its binding activity (3D7 AMA1), (C) stable 
PfRON2L-Ig expression (anti-hIgG) in 293T cells over two weeks, with reference line showing the 
signal level of 2 μg/mL human IgG, and (D) PfRON2L-Ig showing similar binding activity to 




Optimization of inhibitor purification methods 
Next, in order to obtain a relatively small volume of supernatant for purification, we tested 
two Ig precipitation methods using ammonium sulfate and sodium sulfate. We found that 
inhibitor precipitated using (NH4)2SO4 demonstrated higher level of human IgG concen-
tration and stronger binding activity against AMA1 in general. In addition, we detected 
less inhibitor remained in the supernatant after (NH4)2SO4 precipitation (Figure 10A & 
10B). Next, we evaluated the inhibitor’s binding activity against 3D7 AMA1 under varying 
storage conditions by ELISA. Here we focused on analyzing how different storage buffers 
(1× PBS, DMEM, and incomplete RPMI) and inhibitor’s concentration level (before and 
after dialysis) would affect its bio-activity after two weeks of storage at 4 °C. Aliquot of 
each sample stored at −80 °C for the same period of time was used as control. Remarkably, 
our data suggested that (NH4)2SO4 precipitated inhibitor stored in incomplete RPMI had a 
well preserved bio-activity, in contrast to different degrees of activity loss observed in all 
other conditions (Figure 11A-D). We also showed that higher concentration did not have 
detectable negative effect on protein’s activity (Figure 11E).  
 
Figure 10. Protein precipitation using two different methods. Inhibitor concentration (anti-
hIgG) and binding activity (3D7 AMA1) evaluation after (A) (NH4)2SO4 and (B) Na2SO4 
precipitation by ELISA. 
30 
 
Therefore, based on these evidences, we chose to use ammonium sulfate precipitation 
method for subsequent experiments, and the purified inhibitor protein was stored in incom-
plete RPMI at 4 °C.  
 
Figure 11. Stability evaluation of PfRON2L-Ig by ELISA. After storing at 4 °C for two weeks, 
protein concentration was quantified (A&C, anti-hIgG) and its binding activity against 3D7 AMA1 
was evaluated (B&D, 3D7 AMA1) by ELISA. (E). (NH4)2SO4 precipitated inhibitor stored in 
incomplete RPMI at 4 °C showed no detectable change in activity after two weeks. 
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To purify RON2L-Ig, we used Protein G agarose column due to its ability to bind the Fc 
region of the immunoglobulin molecules. The (NH4)2SO4 precipitated pellets from the cell 
culture supernatant was dissolved in small volume of 1× PBS and allowed to flow through 
the column as described in the Methods section. After Protein G column purification, the 
purified RON2L-Ig sample was loaded on an SDS-PAGE protein gel. Coomassie Blue 
stained protein gel showed that comparing to the supernatant before purification, a concen-
trated band appeared at approximately 150 kDa (Figure 12A), suggesting the inhibitor with 
a human IgG backbone successfully isolated from the supernatant. This was confirmed by 
western blot using an anti-human IgG antibody (Figure 12B). IFA images showed an over-
lap signal between the AMA1 (labeled with anti-AMA1 antibody) and inhibitor PfRON2L-
Ig (labeled with anti-human antibody), confirming that our inhibitor is able to bind natural 
parasite as designed (Figure 12C).  
Figure 12. Purified PfRON2L-Ig characterization. (A) Coomassie stained SDS-PAGE gel and 
(B) western blot of purified RON2L-Ig showing a concentrated band at approximately 150kDa. 
(C) IFA of P. falciparum showing co-localization between RON2L-Ig (Green signal) and anti-
AMA1 Ab (Red signal). 
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Inhibitor effectively neutralizes parasite invasion in vitro 
After demonstrating that the inhibitor does bind to natural AMA1 on the parasite surface, 
our next step is to confirm that, as hypothesized, the inhibitor can efficiently block the 
parasite invasion by competitively bind to AMA1 ligands on the parasite surface. To do 
this, parasites were first synchronized to late schizont stage, then GIA was performed by 
adding purified inhibitor PfRON2L-Ig to P. falciparum parasite culture. After 48 hours, 
the samples were stained with MitoTracker and SYBR Green, and flow cytometry was 
used to measure cell fluorescence. Viable parasites were labeled with MitoTracker dyes, 
which permanently bound to mitochondria of the cells, whereas SYBR Green signal indi-
cated the parasite-infected RBCs. Parasitemia was determined by the percentage of the 
cluster which is positive for both SYBR Green and MitoTracker.  
 
Figure 13. Growth inhibition assay for 48 hours. Parasitemia of (A) no-drug control parasite 
culture, (B) parasite culture added with inhibitor PfRON2L-Ig (final concentration 300 μg/mL), 
(C) parasite culture added with EGTA (final concentration 4 mM), and (D) parasite culture added 
with E64D (final concentration 50 μM). (E) Dose-dependent inhibitory effect of PfRON2L-Ig in 
3D7 P. falciparum cultures. 
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Clusters with distinct SYBR Green signal strength represent various stages (e.g. ring stage, 
schizont stage) of the parasites inside infected RBCs (Figure 13A). The original concen-
tration of the protein G column purified inhibitor quantified by ELISA was approximately 
600 μg/mL (making the first dilution 300 μg/mL) and resulted in a 94% of inhibition effect 
(Figure 13B). The positive controls where final concentration of 4 mM EGTA or 50 μM 
E64D in the parasite culture and showed 90% and 95.6% of inhibition effect respectively 
(Figure 13C & 13D). Dose-dependent inhibitory effect was observed for serial diluted 
inhibitor (Figure 13E). 
rAAV transduction induces in vivo expression of the inhibitor 
Inhibitor level in the serum continued to increase starting from week 0 after recombinant 
AAV transduction and finally plateaued at 700-800 μg/mL starting from week 3 and week 
4 for 2A10 and RON2L-Ig transduced mice respectively (Figure 14A). This level of ex-
pression was compatible to the results from previous studies68,71. As discussed previously, 
the inhibitor is a foreign peptide RON2L fused to a human Ig backbone, therefore we also 
tested if either part of the fused protein induced an immune response in these mice. ELISA 
data of mice serum on plates coated with human IgG antibody and RON2L peptides 
showed only a very low level of anti-human Ig antibody in these animals (Figure 14B). 
Importantly, the anti-RON2L antibody in the mice serum was absent or minimal (Figure 









Figure 14. In vivo expressed inhibitor PyRON2L-Ig characterization by ELSIA. (A) Human 
IgG level in mouse sera after recombinant viral vector transduction followed for 8 weeks. (B) Anti-





In 2016, 21 countries were identified by WHO as having the most potential to eliminate 
malaria by 2020, these include Mexico, Belize, El Salvador, Costa Rica, Ecuador, Suri-
name, Paraguay, Cabo Verde, Botswana, Algeria, South Africa, Comoros, Saudi Arabia, 
Iran, Nepal, Bhutan, China, Malaysia, Timor-Leste, and South Korea84. To date Paraguay 
is the only country that has been certified to be malaria-free by WHO, and while most of 
the 21 countries are on track to malaria elimination, there are still a few countries have 
concerning high yearly indigenous cases. For example, South Africa has close to 20,000 
indigenous cases in 2017 alone, which is a dramatic increase comparing to that of 20162.  
Previously, antibodies that target circumsporozoite proteins (CSP), such as monoclonal 
antibody 2A1085,86, more recently identified CIS4387, and two monoclonal antibodies 
mAbs 311 and 31788, are the main focus of research for rational vaccine design or passive 
immunization. These mAbs mainly target a central region consisting predominantly of 
NANP repeats in the N-terminal domain of the Pf CSP, which is essential for Plasmodium 
life cycle and parasite development in the mosquito vector as well as in the mammalian 
host89–91. NANP is found to be conserved among P. falciparum isolated from diverse geo-
graphical locations86, rendering it a potentially ideal target for P. falciparum immunization. 
B-cell response elicited by CSP results in production of antibodies that target mainly the 
central region of NANP repeats, protecting animal models from malaria infection92,93. 
However, clinical trials of RTS,S vaccine designed based on PfCSP showed minimal and 
short-term protection effect in the absence of repeated immunization10,94,95, possibly due to 
the lack of efficient formation of protective B cell memory96,97. 
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The path to achieving the final goal of GTS to have at least 35 countries eliminate malaria 
before 2030 seems full of challenges, especially with the recent emergence of multi-drug 
resistant parasite strains. The current situation warrants us to seek alternative non-tradi-
tional solutions beyond current scope. Inspired and encouraged by the report published in 
2015, in which the inhibitor eCD4-Ig delivered by viral vector in rhesus macaques and 
showed great protection effect against SHIV infection. This artificially designed inhibitor 
binds avidly and cooperatively to the HIV-1 envelope glycoprotein (Env) and is shown to 
be even more potent than the best broadly neutralizing antibody (bNAbs)72. In this study, 
preliminary data of a novel inhibitor PfRON2L-Ig with a human immunoglobulin back-
bone has shown promising inhibitory effect on Plasmodium falciparum invasion process. 
We showed that the inhibitor can be produced by mammalian cells as correctly folded, 
intact fusion protein, and it can bind to multiple strains of AMA1 molecules. IFA data 
showed that the inhibitor can bind to the natural AMA1 molecule on the surface of the 
parasite, and GIA data showed that it efficiently blocks the parasite invasion process in 
vivo. Next, we used an adeno-associated viral vector to deliver the gene of the inhibitor in 
our in vivo mice model and we detected high expression level in their bloodstream (~700 
μg/mL in average). In theory, in addition to the expected direct blocking of invasion by 
parasites, it is possible that our inhibitor PfRON2L-Ig could also come to effect by (1) the 
neutralization of parasites by agglutination, (2) the initiation of the complement cascade 
resulting in further opsonization and lysis, and (3) the recruitment of neutrophilic granulo-
cytes and monocytes. However, analysis of these immune responses is beyond the scope 
of this study thus will not be further discussed here.  
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Despite of the strong inhibitory effect observed in GIA experiments, activity loss of the 
purified inhibitor PfRON2L-Ig was observed after two weeks of storage at 4 °C (Figure 
11), likely due to protein’s instability. The close proximity between the RON2L peptide on 
the heavy and light chains might lead to the formation of cross-disulfide bond between the 
RON2L peptides on the heavy and the light chain thus the disruption of the tertiary struc-
ture. A potential solution to the problem could be instead of a tetravalent inhibitor (i.e. all 
four variable regions on a single immunoglobulin are replaced with RON2L), a divalent 
inhibitor with only the heavy chains replaced by RON2L should be tested. This could pre-
sumably avoid close contact between two chains and consequently the potential cross-di-
sulfide bond formation. Another possibility is that the instability of the fusion protein was 
caused by the flexible linker sequence attached between RON2L and Ig. It was reported 
that the secondary structure, the hydrophobicity, the amino acid residues, and the length of 
the linker may play important role in the yield and the bioactivity of fusion proteins98. For 
example, in the case of a bifunctional enzyme that is the fusion protein of β-glucanase and 
xylanase, compared to flexible linkers, the insertion of longer helical linkers (EAAAK)n (n 
= 1-3) appeared to be more efficient in increasing the thermal stability99. It is likely that 
the rigid structure of the α-helical linker might provide space for different domains of the 
fusion protein to fold and function independently. Another possibility is to increase the 
length of linker to provide better stability. The linker used in this study has only a single 
repeat of Gly-Gly-Ser-Gly between RON2L peptide and the constant region of Ig, therefore 
it is possible that by adjusting the length and the secondary structure of the linker, the 
thermal stability could be improved.  
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Our next goal is to evaluate inhibitor’s protection efficiency in the process of sporozoite 
(the form injected by infected mosquitoes) entry into hepatocytes. IFA will be performed 
to verify it binding to the surface of sporozoites, which will be obtained by dissecting in-
fected mosquitoes. Gliding motility assay will also be performed to assess the effect of 
inhibitor PyRON2L-Ig on parasite motility. Next, mice will first be injected intramuscu-
larly with the optimal number of AAV-PyRON2L-Ig to have the inhibitor expressed at 
high level as described above, then 2 to 4 weeks after transduction will be challenged by 
intravenous injection of 1,000 sporozoites isolated from the salivary gland of infected mos-
quitoes. Mice will be sacrificed 36 hours after challenge, before the release of hepatic mer-
ozoites that infect RBC, and parasite load in the liver will be measured by qPCR using 
primers specific for Plasmodium 18S rRNA. Completion of this arm of the study will con-
firm that in addition to prevention of blood stage infection, which leads to the clinical 
symptoms, the inhibitor is also able to prevent the initiation of infection and in vivo trans-
mission from the very start—sporozoite invasion into hepatocytes.  
In spite of the potential advantages described above, preexisting immunity against viral 
capsid, which can lead to low transduction efficiency of rAAV, has been one of the biggest 
concerns in the use of the VIP technology in human trials100,101. For example a study de-
tected prevalence of IgG against most of the commonly used AAV serotypes in human: 
anti-AAV1 and -AAV2 total IgG determined by enzyme-linked immunosorbent assay 
showed 67% and 72%, higher than those of anti-AAV5 (40%), anti-AAV6 (46%), anti-
AAV8 (38%), and anti-AAV9 (47%)102. In addition, studies also identified CD4+ and 
CD8+ T cell epitopes for AAV2103–105 and AAV8106. New approaches such as engineering 
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viral capsids by directed evolution could lead to discovery of low immunogenic viral vec-
tors thus an improved transduction efficiency107. It is important to evaluate the anti-AAV 
capsid antibody level in the animal model during the future experiments. In addition to the 
immunity against viral vector, there is also the potential immune response against the arti-
ficially designed inhibitor (i.e. elicitation of anti-inhibitor antibody). For example, a recent 
study showed that the artificial inhibitor eCD4-Ig designed for HIV induced strong host 
immune response due to the immunogenicity of IgG1-Fc region of the inhibitor; while in 
contrast, eCD4-Ig bearing a rhesus IgG2-Fc domain showed reduced immunogenicity and 
correlated with stronger protection in rhesus macaques108. Although our preliminary data 
showed no detection of anti-inhibitor antibody in the mouse sera at week 8 (Figure 14B & 
14C), it does not guarantee a similar level of immune response would be seen in NHP or 
human. Further experiments are required to examine the inhibitor’s immunogenicity.  
In conclusion, our study has tested the engineered P. falciparum self-targeting entry inhib-
itor RON2L-Ig both in vitro and in vivo to evaluate (1) its inhibitory effect for blocking 
parasite invasion and (2) its expression level in animal sera when delivered by a viral vec-
tor. Our preliminary data showed that the inhibitor can efficiently inhibit parasite invasion 
in vitro presumably by competitively binding to AMA1 molecule on the parasite surface, 
and it can also be expressed at high level in vivo in a mouse model. However, further studies 
are needed to optimize its stability and confirm both its inhibitory effect in vivo. This study 
aims to eventually provide a novel solution to the malaria infection by using viral vector to 
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